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Abbreviations
and Acronyms
ACS = acute coronary
syndromes(s)
CI = conﬁdence interval
CK-MB = creatine kinase-
myocardial band
cTn = cardiac troponin
HR = hazard ratio
IQR = interquartile range
MI = myocardial infarction
NSTE = non–ST-segment
elevation
PCI = percutaneous coronary
intervention
ULN = upper limit of normal
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245The clinical signiﬁcance and interpretation of cTn ele-
vation following PCI is even more controversial for patients
presenting with MI. Differentiating post-PCI cTn increase
from that of the natural evolution of the presenting MI is
challenging but essential to properly interpret the clinical
relevance of revascularization-related necrosis. In addition,
because of the well-known prognostic role of cTn elevation in
ACS, it is unclear whether a new cTn release at the time of
PCI provides additional prognostic signiﬁcance (9).
Using a large cohort of patients with non–ST-segment
elevation (NSTE) ACS from the combined EARLY ACS
(Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Se-
gment Elevation Acute Coronary Syndrome) and SYNERGY
(Superior Yield of the New Strategy of Enoxaparin, Revas-
cularization and Glycoprotein IIb/IIIa Inhibitors) trials’
datasets, we identiﬁed patients in whom cardiac biomarker
elevation associated with PCI could be distinguished from
elevation associated with the presenting MI. In that cohort,
we assessed the association between cTn and CK-MB
elevation after PCI and 1-year mortality.Methods
Dataset. Analyses were conducted using datasets from the
EARLY ACS and SYNERGY trials, which have been
published (10,11). These trials enrolled patients with NSTE
ACS (N ¼ 9,406, EARLY ACS; N ¼ 10,027, SYNERGY)
with at least 2 of the following criteria: age 60 years;
cardiac biomarkers (cTn or CK-MB) above the local ULN;Figure 1 Representative Example of a Patient Plot of cTn and CK-M
cTn ¼ cardiac troponin; CK-MB ¼ creatine kinase-myocardial band; DISC ¼ discharge; IE
ULN ¼ upper limit of normal.or ST-segment depression (or
transient elevation) 1 mm. In
addition, the EARLY ACS trial
enrolled patients with all 3 of the
following criteria: age 50 to 59
years; positive cardiac bio-
markers; and history of coronary
artery disease. In both trials,
patients were planned to undergo
an early invasive management
strategy. In EARLY ACS and
SYNERGY, 84% of patients had
elevated cardiac biomarkers at
baseline. For this analysis, we
included all patients who under-
went PCI during the index
hospitalization (N ¼ 10,199).
The EARLY ACS andSYNERGY trials were approved by the institutional review
board or ethics committee of each participating site, and all
patients gave written informed consent. The current analyses
were approved by the institutional review board of Duke
University Medical Center.
Assessment of cardiac biomarker trends. The SYNERGY
and EARLY ACS trials mandated the collection of cardiac
biomarkers every 8 h during the ﬁrst 24 h after randomiza-
tion, and then daily throughout the hospitalization. Among
patients undergoing PCI, cardiac biomarker collection was
required before the procedure and every 8 h for 24 hB Temporal Trends During Index Hospitalization
¼ index event; PCI ¼ percutaneous coronary intervention; R ¼ randomization;
Figure 2
Patients Flow Following
cTn Graphic Trend Interpretation
MI ¼myocardial infarction; NSTE ACS ¼ non–ST-segment elevation acute coronary
syndrome; other abbreviations as in Figure 1.
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246following the procedure. In addition, cardiac biomarker
measurements not mandated by protocol but performed as
part of the standard of care from hospital presentation to
discharge were recorded in the trial databases.
Troponin and CK-MB time-trends plots. We created
plots representing temporal trends of cTn and CK-MB
values during the index hospitalization. A plot was gener-
ated for each patient undergoing PCI. Because values of
cardiac biomarkers were analyzed in local laboratories of
participating sites, values were indexed by the local ULN.
Each graph listed troponin and CK-MB values on the y-axis
and time on the x-axis. Key benchmarks included time
of index event, randomization, PCI, PCI þ 24 h, and
discharge. A representative example of the plots is provided
in Figure 1.
Two independent reviewers (P.T. and S.L.) visually
reviewed each plot. Disagreements were resolved by rereview
and consensus. For cases that could not be solved by visual
interpretation only, reviewers accessed the actual values. The
major goal was to identify patients in whom biomarkers
were decreasing or stable before PCI and to separate them
from patients in whom biomarkers were increasing before
PCI. Decreasing trends were deﬁned by values that were
lower than prior values, and stable trends were deﬁned by
identical values. For patients with increasing values before
PCI, post-PCI biomarkers were considered to be not
interpretable, as those elevations could not be separated
from natural evolution of the presenting MI. These patients
were excluded from subsequent analyses. The initial agree-
ment between the 2 independent reviews in the application
of these criteria was overall 94.3% for cTn and 94.2% for
CK-MB.
The trends for troponin and CK-MB were read inde-
pendently, and the results were applied to the respective
biomarker analyses. Through the plot review process, patients
were classiﬁed into the following groups: 1) decreasing or
stable biomarker levels before PCI; or 2) increasing
biomarker levels before PCI. Patients with decreasing
or stable biomarker levels before PCI were further grouped
into: 1) patients with new cardiac biomarker increase after
PCI (in the 24 h following PCI); or 2) patients without new
cardiac biomarker increase after PCI. In patients with new
post-PCI increases in biomarker levels, reviewers identiﬁed
the last value preceding the (re-)elevation and the peak value
associated with the elevation.
Statistical analysis. We performed 2 sets of analyses, 1
each with the following variables of interest: 1) post-PCI
cTn elevation; and 2) post-PCI CK-MB elevation. We
aimed to evaluate the prognostic value of post-PCI cTn
elevation for subsequent mortality. Although the primary
focus of the analysis was cTn, because CK-MB is a more-
established marker for post-PCI myocardial necrosis, the
CK-MB analysis was also performed to help interpret the
ﬁndings of the cTn analyses.
The main outcome for the analysis was 1-year all-cause
mortality. For the analysis of post-PCI cTn, we used Coxproportional hazards models to examine the association of the
following values with 1-year mortality: 1) peak cTn after PCI;
and 2) absolute post-PCI cTn increase (the difference
between peak cTn after PCI and the last value preceding the
[re-]elevation). Separate models were created for peak cTn
and the absolute post-PCI increase. Models were stratiﬁed by
trial and adjusted for covariates of interest derived from the
1-yearmortality model generated from theEARLYACS trial
database (age, ST-segment changes, baseline Killip class,
peripheral artery disease history, estimated creatinine clear-
ance, weight, previous MI, heart rate, previous PCI or coro-
nary artery bypass graft surgery, systolic blood pressure, female
sex, current smoker, diabetes, and heart failure history). In
addition, the pre-PCI cTn peak was included in the model to
adjust for risk of death related to the baseline cTn elevation.
Because the relationship between peri-PCI cTn values
and 1-year mortality was nonlinear, spline transformation
was implemented before modeling. The assumption of
proportional hazards was tested and conﬁrmed. The rela-
tionship of peri-PCI cTn elevation with 1-year mortality is
presented as hazard ratio (HR) per 10-fold increase (95%
conﬁdence interval [CI]).
Analyses to determine the association of post-PCI CK-
MB with 1-year mortality were performed using an identical
methodology but with post-PCI CK-MB peak as the vari-
able of interest.
Using the models described, we generated adjusted
survival predictions with 95% CIs to calculate predicted
survival at pre-speciﬁed thresholds of post-PCI cTn and
CK-MB peak levels. We used bootstrapping to calculate the
95% CIs. Survival was then transformed to mortality (1-year
survival).
Figure 3 Distribution of Degrees of Elevation of cTn After PCI
Abbreviations as in Figure 1.
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247Results
Post-PCI cardiac biomarker elevation. Of 10,199 patients
who underwent PCI during the index hospitalization in
EARLY ACS and SYNERGY, 4,198 (41.2%) patients had
increasing cTn levels before PCI and 229 (2.2%) had
missing post-PCI values and were excluded from the anal-
yses (Fig. 2). The remaining 5,772 (56.6%) had descending
or stable cTn levels before PCI: 4,276 (41.9%) had a new
increase in cTn level in the 24 h following PCI, and 1,496
(14.7%) had no new increase in post-PCI cTn level. Among
patients included in the analysis, the median number of cTn
samples obtained locally prior to PCI was 4 (interquartile
range [IQR]: 3 to 6). In the 24 h after PCI, the median was
3 (IQR: 2 to 4).
Figure 3 shows the distribution of degrees of elevation of
post-PCI cTn above the local ULN. Baseline demographics,
cardiovascular history, and presenting characteristics by
degree of post-PCI cTn peak level are shown in Table 1.
In the CK-MB analysis of 10,197 patients, 2,946 (28.9%)
had increasing values prior to PCI, 820 (8.0%) had missing
post-PCI values, and 6,431 (63.1%) had decreasing or stable
values pre-PCI. Among those with decreasing or stable
levels prior to PCI, 4,174 had a new increase in CK-MB
values following the PCI, and 2,257 had no increase.
Most patients (n ¼ 3,243, 77.7%) with increased CK-MB
values after PCI had peak values of 3 ULN; 402
(9.6%) had peak values of CK-MB >3 to 5 ULN, 298
(7.1%) had peak values of >5 to 10 ULN, and 231
(5.5%) had peak values of >10 ULN.
There were 4,395 (43.1%) patients in whom both
cTn and CK-MB levels were evaluable after PCI; cTn was
the only evaluable marker for 1,376 of 10,199 (13.5%)
patients, and CK-MB was the only evaluable post-PCI
marker for 2,036 of 10,197 (20.0%) patients. Neither cTn
nor CK-MB could be evaluated after PCI for 2,390 (23.4%)
patients.
Troponin, CK-MB, and 1-year mortality. The relation-
ships between: 1) peak cTn after PCI and absolute increase incTn after PCI; and 2) 1-year mortality were nonlinear with
major inﬂections at 100 ULN (Fig. 4), and these variables
were spline-transformed for modeling. In the adjusted
model, peak cTn after PCI was signiﬁcantly associated with
1-year mortality: for each 10 ULN increase in cTn, there
was a 7% relative increase in the hazard of 1-year mortality
(HR: 1.07, 95% CI: 1.02 to 1.11; p ¼ 0.0038). The asso-
ciation with 1-year mortality was signiﬁcant also above 100
ULN (HR: 1.02, 95% CI: 1.00 to 1.03; p ¼ 0.007).The
absolute post-PCI cTn increase was signiﬁcantly associated
with 1-year death: for each 10 ULN increase above the
pre-elevation value, there was a 6% relative increase in the
hazard of mortality (HR: 1.06, 95% CI: 1.01 to 1.11;
p ¼ 0.0275). A signiﬁcant association with 1-year death was
also observed above 100 ULN (HR: 1.02, 95% CI: 1.01 to
1.04; p ¼ 0.0027).
The relationships of peak CK-MB after PCI and absolute
increase in CK-MB after PCI were nonlinear with respect to
1-year mortality (Fig. 5), with major inﬂections at 5 ULN,
and these variables were spline-transformed for modeling. In
the adjusted model, peak post-PCI CK-MB was signiﬁ-
cantly associated with 1-year mortality: for each 1 ULN
increase in CK-MB peak, there was a 13% increase in the
hazard of 1-year death (HR: 1.13, 95% CI: 1.05 to 1.21;
p ¼ 0.0013). The association was maintained above 5
ULN (HR: 1.03, 95% CI: 1.02 to 1.04; p < 0.0001). The
absolute post-PCI CK-MB increase above the pre-elevation
value was also signiﬁcantly associated with 1-year mortality
(per 1 ULN increase up to 5 ULN [HR: 1.12, 95% CI:
1.03 to 1.21; p ¼ 0.0057]; above 5 ULN [HR: 1.03, 95%
CI: 1.02 to 1.04; p < 0.0001]).
As a sensitivity analysis, we also assessed the predictive
value of post-PCI cTn peak in the group of patients in
whom both cTn and CK-MB could be assessed after
PCI, and the results were not substantively different from
the results just reported: for each 10 ULN increase in
cTn there was a 9% relative increase in the hazard of
1-year mortality (HR: 1.09, 95% CI: 1.03 to 1.14;
p ¼ 0.0009).
Adjusted estimated risk of death at different thresholds of
biomarker elevation. Using the models generated for the
associations of post-PCI peak cTn and peak CK-MB with
1-year mortality, we determined adjusted estimated risks of
death at different threshold levels of biomarker elevation
(Table 2). The adjusted estimated risk of 1-year mortality for
a CK-MB peak >3 ULN was 5.1% (95% CI: 4.2% to
5.9%), whereas for cTn peak >3 ULN, it was 3.5% (95%
CI: 2.9% to 4.1%). A cTn threshold >60 ULN provided
a 4.9% (95% CI: 3.9% to 6.0%) estimated risk of death,
comparable to CK-MB >3 ULN. A cTn threshold
>100 ULN provided a 6.2% (95% CI: 4.5% to 8.4%)
estimated risk of death, similar to a CK-MB threshold of
>5 ULN.
Of note, the proportion of patients with cTn elevation
>60 ULN was 13.5%, which is similar to the proportion
Table 1 Baseline Characteristics According to Extent of Troponin Elevation Above ULN
No Elevation
(n ¼ 1,496)
0–3 ULN
(n ¼ 918)
>3–5 ULN
(n ¼ 381)
>5–10 ULN
(n ¼ 635)
>10–20 ULN
(n ¼ 689)
>20–50 ULN
(n ¼ 754)
>50 ULN
(n ¼ 898)
Not Evaluable
(n ¼ 4,427)
Trial
EARLY ACS 914 (61.1) 450 (49.0) 200 (52.5) 331 (52.1) 385 (55.9) 412 (54.5) 535 (56.9) 2,325 (52.5)
SYNERGY 582 (38.9) 468 (51) 181 (47.5) 304 (47.9) 304 (44.1) 342 (45.4) 363 (40.4) 2,102 (47.5)
Demographics
Age, yrs 66.2 (59.2–73.6) 67.8 (61.0–74.1) 67.6 (60.0–75.0) 67.9 (60.1–74.3) 67.0 (60.4–74.0) 67.0 (60.0–75.0) 68.0 (60.0–75.1) 66.0 (58.0–74.0)
Female 440 (29.4) 320 (34.9) 121 (31.8) 185 (29.1) 220 (31.9) 209 (27.7) 245 (27.3) 1,304 (29.5)
Weight, kg 80.8 (70.0–92.0) 79.0 (70.0–90.0) 81.0 (70.0–91.0) 80.0 (71.0–91.0) 80.0 (70.0–90.3) 80.0 (70.9–90.0) 80.0 (70.0–90.0) 80.0 (70.0–91.0)
CV history
Diabetes 432 (28.9) 258 (28.1) 112 (29.4) 171 (26.9) 184 (26.7) 196 (26.0) 237 (26.4) 1,235 (27.9)
Hypertension 981 (65.6) 647 (70.5) 283 (74.3) 436 (68.7) 478 (69.4) 489 (64.9) 581 (64.7) 2,947 (66.6)
CHF 137 (9.2) 88 (9.6) 40 (10.5) 56 (8.8) 49 (7.1) 45 (6.0) 59 (6.6) 414 (9.4)
MI 354 (23.7) 266 (29.0) 105 (27.6) 176 (27.8) 172 (25.0) 204 (27.1) 232 (25.8) 1,158 (26.2)
PAD 135 (9.0) 95 (10.3) 28 (7.3) 63 (9.9) 80 (11.6) 65 (8.6) 93 (10.4) 360 (8.1)
PCI 346 (23.1) 282 (30.7) 99 (26.0) 165 (26.0) 166 (24.1) 152 (20.2) 179 (19.9) 1,006 (22.7)
CABG 214 (14.3) 163 (17.8) 50 (13.1) 101 (15.9) 101 (14.7) 116 (15.4) 124 (13.8) 638 (14.4)
Current smoker 451 (30.1) 237 (25.8) 111 (29.1) 164 (25.8) 178 (25.8) 202 (26.8) 261 (29.1) 1,286 (29.0)
Presentation
Heart rate, beats/min 72 (64–84) 72 (62–82) 74 (64–85) 72 (63–83) 73 (64–84) 73 (64–84) 74 (64–85) 73 (64–84)
SBP, mm Hg 140 (123–154) 140 (122–145) 140 (124–160) 140 (122–158) 140 (123–158) 139 (121–156) 139 (121–154) 138 (120–155)
Creatinine clearance, ml/min 79.0 (60.3–101.3) 73.7 (55.6–95.9) 76.5 (57.7–102.0) 75.9 (57.7–97.8) 77.5 (58.9 –99.1) 77.0 (59.2–99.8) 76.5 (56.9–97.6) 78.5 (59.7–101.1)
Killip class
1 1,351 (91.3) 827 (91.4) 343 (92.5) 576 (91.6) 640 (93.8) 673 (90.2) 796 (89.2) 3,934 (90.5)
2 101 (6.8) 65 (7.2) 25 (6.7) 44 (7.0) 32 (4.7) 57 (7.6) 80 (9.0) 327 (7.5)
3 20 (1.4) 11 (1.2) 3 (0.8) 6 (1.0) 7 (1.0) 11 (1.5) 13 (1.5) 72 (1.7)
4 7 (0.5) 2 (0.2) 0 (0.0) 3 (0.5) 3 (0.4) 5 (0.7) 3 (0.3) 13 (0.3)
ST changes 813 (54.4) 543 (59.2) 186 (58.8) 312 (49.3) 355 (51.5) 384 (51.1) 514 (57.2) 2,531 (88.6)
Positive markers 1,285 (85.9) 653 (71.1) 341 (89.5) 589 (92.8) 642 (93.2) 698 (92.6) 858 (95.5) 3,921 (88.6)
Arrival to randomization, h 6.3 (3.4–11.3) 6.5 (3.5–11.7) 6.9 (3.4–11.7) 6.8 (3.6–11.3) 6.0 (3.4–10.9) 6.4 (3.6–10.8) 5.5 (3.0–9.4) 5.4 (2.9–9.8)
Randomization to PCI, h 23.9 (18.5–46.5) 24.1 (18.0–47.2) 22.8 (17.1–44.2) 22.5 (16.7–41.3) 23.1 (17.6–44.3) 23.4 (17.4–42.9) 22.1 (16.4–38.6) 20.5 (12.0–40.4)
CAD extent
0 vessels 15 (1.0) 8 (0.9) 1 (0.3) 6 (1.0) 6 (0.9) 10 (1.3) 10 (1.1) 41 (0.9)
1 vessel 676 (45.5) 425 (46.7) 157 (42.0) 239 (37.9) 274 (40.2) 280 (37.3) 315 (35.3) 1,800 (41.1)
2 vessels 433 (29.1) 262 (28.8) 102 (27.3) 211 (33.5) 228 (33.4) 258 (34.4) 307 (34.4) 1,360 (31)
3 vessels 363 (24.4) 216 (23.7) 114 (30.5) 174 (27.6) 174 (25.5) 202 (26.9) 261 (29.2) 1,180 (26.9)
Left main 63 (4.2) 38 (4.2) 14 (3.7) 22 (3.5) 32 (4.7) 39 (5.2) 48 (5.4) 200 (4.6)
Values are n (%) or median (interquartile range).
CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; CHF ¼ congestive heart failure; CV ¼ cardiovascular; EARLY ACS ¼ Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndromes; MI ¼ myocardial infarction;
PAD ¼ peripheral artery disease; PCI ¼ percutaneous coronary intervention; SBP ¼ systolic blood pressure; SYNERGY ¼ Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors; ULN ¼ upper limit of normal.
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Figure 4
Adjusted Relationship Between
Post-PCI Troponin Peak and 1-Year Mortality
Please see text for estimate adjustments. CI ¼ conﬁdence interval; HR ¼ hazard
ratio; PCI ¼ percutaneous coronary intervention.
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249of patients with CK-MB elevation >3 ULN (14.5%).
Also, the proportion of patients with cTn elevation >100
ULN was 8.8%, which is comparable to the proportion of
patients with CK-MB elevation >5 ULN (8.2%).
Discussion
A graphic-based methodology to review biomarkers trends
over time allows identiﬁcation of patients with NSTE ACS
in whom a rise in post-PCI cardiac biomarkers can be
distinguished from a rise in cardiac biomarkers due to the
presenting MI. In those patients, we observed a statistically
signiﬁcant association between post-PCI cTn peak level and
1-year mortality. A statistically signiﬁcant association wasFigure 5
Adjusted Relationship Between Post-PCI CK-MB
Peak and 1-Year Mortality
Please see text for estimate adjustments. Abbreviations as in Figures 1 and 4.also observed between post-PCI peak CK-MB and 1-year
mortality. Higher cTn elevation thresholds provided esti-
mated mortality risks that were similar to the currently
adopted CK-MB thresholds.
Post-PCI biomarker and the diagnosis of MI. Cardiac
troponin assays can detect small amounts of myocardial
necrosis; therefore, the clinical relevance of increased cTn
levels following PCI has been questioned, particularly in the
absence of observed procedural complications and clinically
apparent consequences of myonecrosis (8). Similar argu-
ments have been made regarding CK-MB elevation after
PCI, but available evidence overall supports a correlation
between CK-MB elevation after PCI and in-hospital
adverse events and long-term mortality (4–6,12). Proposed
CK-MB thresholds to diagnose procedure-related MI have
historically been 3 or 5 ULN (3,8,13).
Cardiac troponin elevation after PCI correlates with
the presence of late enhancement on cardiac magnetic
resonance imaging, an indicator of myocardial scarring (14).
Nonetheless, the results of studies correlating post-PCI cTn
elevation with long-term outcomes have conﬂicted (6,15–19).
Studies assessing the prognostic value of post-PCI cTn
levels in patients with ACS have included patients with and
without elevated pre-PCI cardiac biomarkers but have not
speciﬁcally addressed whether elevated post-PCI cTn values
were part of the expected rise related to an initial MI or if
they represented new cTn release related to the PCI.
This difference is key to understanding the prognostic
implications of post-PCI cTn increases (20). The current
universal deﬁnition of MI document recommends that
trends in biomarker levels before PCI should be evaluated in
order to implement a biomarker-based deﬁnition of MI (3).
In the present study of a large, multicenter cohort of
patients with ACS, in whom serial collection of cardiac
biomarkers was mandated by protocol, we reviewed trends in
cardiac biomarkers of each patient undergoing PCI during
the index hospitalization to identify those in whom cTn was
decreasing or stable prior to PCI. In those patients, post-
PCI elevations could be clearly distinguished from thoseTable 2
Adjusted Probability of 1-Year Mortality by
Thresholds of Biomarker Elevation After PCI
Cutoff,
 ULN
Patients Above Cutoff, %
Adjusted Predicted Mortality
With 95% CI
Troponin CK-MB Troponin CK-MB
>3 58.2 14.5 3.5 (2.9–4.1) 5.1 (4.2–5.9)
>5 51.6 8.2 3.5 (2.9–4.2) 6.3 (4.7–7.8)
>10 40.6 3.6 3.6 (3.1–4.3) 7.2 (5.3–8.7)
>20 28.6 1.3 3.9 (3.3–4.5) 9.1 (7.1–11.3)
>50 15.6 d 4.6 (3.8–5.6) d
>60 13.5 d 4.9 (3.9–6.0) d
>80 10.7 d 5.5 (4.2–7.1) d
>100 8.8 d 6.2 (4.5–8.4) d
>200 4.2 d 7.2 (5.3–9.3) d
CI ¼ conﬁdence interval; CK-MB ¼ creatine kinase-MB; ULN ¼ upper limit of normal;d ¼ data not
available.
Tricoci et al. JACC Vol. 62, No. 3, 2013
Post-PCI Troponin Elevation in ACS and Mortality July 16, 2013:242–51
250due to the presenting MI. The cTn curves were screened
using simple visual interpretation of biomarker trends, which
is particularly appealing during the acute event when cardiac
biomarker values may change continuously in relation to the
initial MI, procedures, or spontaneous recurrent events. A
similar approach was adopted by our group to identify
patients with suspected recurrent MI during the acute
hospitalization in recent large ACS trials (2,21). Using this
method, we found that in nearly 60% of patients, post-PCI
cTn values could be differentiated from those due to the
presenting MI and could be assessed for new PCI-related
myocardial necrosis.
After those patients were identiﬁed, we showed that
increased post-PCI cTn levels were highly signiﬁcantly
associated with 1-year mortality. There was a continuous
relationship between increasing post-PCI cTn peak and the
risk of 1-year death, although the hazard associated with
each unit of cTn increase was relatively small (7% increase in
1-year mortality for every 10 ULN increase), reﬂecting the
sensitivity of cTn in detecting small amounts of myocardial
necrosis. In fact, current assays with 10 ULN represent
a rather small increase in ng/ml. For example, a cTnT assay
with a ULN of 0.1 ng/ml (a 10 ULN increase) would be
seen with a value of 1.0 ng/ml, an increase of only 0.09 ng/ml.
Therefore, considering the risk per absolute amount of
myonecrosis detected, these hazards are quite substantial.
The hazard associated with each per-unit increase in CK-
MB, a less sensitive marker, is higher because the relative
changes in level represent much larger infarcts. Together, we
conﬁrm that new, detectable post-PCI myocardial necrosis,
using either cTn or CK-MB, is prognostically relevant in
an NSTE ACS population, and the greater the degree of
myonecrosis, the greater the risk of subsequent mortality.
Our results also conﬁrm that the prognostic value of post-
PCI peak cTn elevation is incremental to that of pre-PCI
cTn elevation, which reﬂects the size of the index MI.
Overall, the data from this study indicate that it is possible to
use cardiac biomarkers to diagnose post-PCI MI in a large
number of patients with ACS presenting with elevated
necrosis biomarkers if trends before PCI are analyzed,
adopting the principles established by the universal deﬁnition
of MI. There is currently no accepted methodology for use of
cardiac biomarkers to diagnosis PCI-related MI in patients
with ACS when necrosis biomarkers are still increasing
before the procedure.
Because of cTn’s sensitivity to detect small areas of
necrosis, thresholds associated with a clinically relevant risk
of adverse events need to be identiﬁed and incorporated into
deﬁnitions of MI. However, this will require the clinical
community and patients to deﬁne “clinically relevant” risk
for death or change in risk from baseline MI. After that, the
thresholds for both spontaneous and PCI-related MI using
either cTn or CK-MB can be determined relative to that
benchmark and then standardized. The revised universal
deﬁnition of MI indicates an identical threshold (>5
ULN) for the diagnosis of peri-PCI MI for cTn andCK-MB, in addition to clinical and angiographic compli-
cations. Yet, because of different sensitivities and, conse-
quently, different hazards of death associated with increased
values of cTn and CK-MB, the threshold for cTn should be
higher than the threshold for CK-MB, if equivalence in
risk-per-unit-increase in level is desired (22). In particular,
we observed that an elevation of cTn >60 ULN carries an
adjusted estimated risk of death similar to a >3 ULN CK-
MB elevation, and an elevation of cTn >100 ULN carries
an adjusted estimated risk of death similar to a >5 ULN
CK-MB. This suggests that increase of cTn and CK-MB at
those thresholds may indicate similar degrees of myocardial
necrosis. Supporting this concept, we observed that the
frequency of CK-MB >3 ULN was similar to the
frequency of cTn >60 ULN, and that the frequency of
CK-MB >5 ULN was similar to the frequency of cTn
>100 ULN.
Study limitations. This study is a post hoc analysis from
2 clinical trial databases, although the data were prospec-
tively collected. Although we adjusted for important clinical
characteristics associated with outcome in our populations,
residual confounding by other factors associated with both
cTn elevation and mortality but not measured or not
included in the model is possible. In particular, the 2 trials
assessed a medical intervention in a general NSTE ACS
population, and the collection of angiographic and proce-
dural details was limited. Although causality between cTn
elevation and mortality is biologically plausible, our study
supports association but does not prove causality, nor does it
address the mechanism through which myonecrosis occurred
and the role it may play in deﬁning the association with
mortality. Our study was based on cTn values obtained
locally, and ratios were based on ULN provided by local
hospitals. We could not account for limitations in assays
used or for appropriateness of ULN chosen at each site, and
we could not consider absolute amounts of myonecrosis. The
results of this study do not imply that cTn elevation after
PCI should be considered equivalent to a recurrent MI;
rather, we aimed to provide data on the correlation between
post-PCI cTn and subsequent mortality. Finally, our results
are not applicable to a large group of patients (more than
40%) who had increasing biomarkers up to the time of PCI.
Conclusions
In a large NSTE ACS population undergoing PCI, a
patient-level assessment of cTn trends allowed for identiﬁ-
cation of approximately 60% of patients in whom new cardiac
biomarker elevation following PCI could be distinguished
from expected elevation due to a presenting MI. In this
group, peak post-PCI cTn was signiﬁcantly associated with
1-year mortality and added prognostic value to cTn elevation
associated with a presenting MI. These results support the
use of cTn, along with CK-MB, for the diagnosis of
PCI-related MI, but they also indicate that thresholds for
cTn and CK-MB will be different for similar risks of
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251mortality. The selection of a threshold for cTn-based diag-
nosis of PCI-related MI should consider both the sensitivity
of the assay (thus, the amount of myonecrosis per unit
increase) and an estimate of what deﬁnes clinically relevant
increases in the rates of complications associated with myo-
necrosis, whether deﬁned by cTn or CK-MB.Reprint requests and correspondence: Dr. Pierluigi Tricoci,
Duke Clinical Research Institute, 2400 Pratt Street, Room 0311,
Terrace Level, Durham, North Carolina 27705. E-mail: pierluigi.
tricoci@duke.edu.REFERENCES
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